PHARMACEUTICAL FORMULATIONS OF BISPHOSPHONATE WITH ENHANCED ORAL BIOAVAILABILITY
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Jan 24, 2013
app pub date -
Oct 19, 2011
filing date -
Jul 22, 2011
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
Disclosed is an oral bisphosphonate formulation characterized by an enhanced clinical bioavailability of bisphosphonate and by the use of phytic acid and a delayed release means for releasing bisphosphonate at a site of the lower gastrointestinal tract. Having a low phytic acid content, the oral bisphosphonate formulation guarantees high safety to the patient. Moreover, the oral formulation is designed to allow the patients to take the medicament, together with food intake, at a bioavailability as high as that of an empty stomach, thus improving the convenience of drug administration for the patient. Therefore, the oral formulation is expected to provide higher therapeutic effects for osteoporosis.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully